Ignite Creation Date:
2025-12-24 @ 7:19 PM
Ignite Modification Date:
2025-12-25 @ 4:58 PM
Study NCT ID:
NCT07216703
Status:
RECRUITING
Last Update Posted:
2025-12-02
First Post:
2025-10-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-12
Start Date Type:
ESTIMATED
Primary Completion Date:
2031-10-29
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-10-29
Completion Date Type:
ESTIMATED
First Submit Date:
2025-10-10
First Submit QC Date:
None
Study First Post Date:
2025-10-14
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-01
Last Update Post Date:
2025-12-02
Last Update Post Date Type:
ESTIMATED